Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hikma Pharmaceuticals ( (GB:HIK) ) has issued an announcement.
Hikma Pharmaceuticals reported that shareholders approved all 22 resolutions at its 2026 annual general meeting in London, including the re‑election of directors, renewal of auditor and authorities to allot shares, disapply pre‑emption rights and repurchase shares. The broad support, with most resolutions receiving more than 95% of votes cast, underpins the company’s current governance structure and financial flexibility.
Investors also backed a final dividend of 48 cents per share, payable on 30 April 2026, and endorsed Rule 9 waivers that permit the Concert Party’s stake to rise to as much as 33.99% of voting share capital through buybacks and share awards. The outcome consolidates control dynamics around Hikma’s largest shareholders while preserving the company’s capacity to return cash and pursue capital management initiatives without triggering a mandatory takeover offer under U.K. rules.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £1800.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on HIK Stock
According to Spark, TipRanks’ AI Analyst, HIK is a Neutral.
The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.
To see Spark’s full report on HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals is a multinational generic and specialty pharmaceutical company listed in London, Nasdaq Dubai and OTC markets. It develops, manufactures and markets a broad portfolio of injectable, branded and non‑injectable generic medicines, with a strong presence in the Middle East and North Africa as well as key global markets.
Average Trading Volume: 1,412,508
Technical Sentiment Signal: Sell
Current Market Cap: £2.91B
For a thorough assessment of HIK stock, go to TipRanks’ Stock Analysis page.